

Etesevimab

Cat. No.:	HY-P99347
CAS No.:	2423948-94-9
Target:	SARS-CoV; Angiotensin-converting Enzyme (ACE)
Pathway:	Anti-infection; Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Etesevimab (JS016) is a recombinant neutralizing human IgG1 anti-SARS-CoV-2 monoclonal antibody ^[1] .
IC ₅₀ & Target	Kd: 6.45 nM (SARS-CoV-2 spike protein) ^[1] IC50: 0.32 nM (spike protein attachment to ACE2) ^[1]
In Vitro	Etesevimab (JS016) binds the spike protein with a K _d of 6.45 nM and blocks spike protein attachment to the human angiotensin converting enzyme 2 (ACE2) receptor with an IC ₅₀ value of 0.32 nM (0.046 µg/mL) ^[1] . Etesevimab blocks viral cell fusion to prevent SARS-CoV-2 invasion of human cells and inhibits viral replication ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Wu X, et al. Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study. Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0035021.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA